Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
Financials
Financial year 2025
Cystic Fibrosis Europe from Oudergem, company number BE0640670746, closed financial year 2025 with a result of € -60,316 after tax. For that financial year Cystic Fibrosis Europe recorded revenue of € 515,834 and equity of € 254,734. Compared with financial year 2024, the result moved from € -50,322 to € -60,316. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 254,734
▼ 19% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -60,316
▼ 20 % more loss than in 2024
Profit after tax over the fiscal year.
€ 277,776
▼ 11% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
€ 189,030
▼ 8% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 219,357
▲ 50% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 15,302
▼ 61% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 91,300 | € 463,076 | € 626,624 | € 515,834 | ▼ 18% |
| Gross margin | € 129,501 | € 156,142 | € 155,937 | € 171,420 | ▲ 10% |
| Profit after taxes | € -19,210 | € -47,537 | € -50,322 | € -60,316 | ▼ € 9,994 |
| Equity | € 413,901 | € 366,364 | € 315,050 | € 254,734 | ▼ 19% |
| Total debts | € 79,319 | € 78,216 | € 285,193 | € 234,660 | ▼ 18% |
| Cash | € 176,870 | € 184,529 | € 311,230 | € 277,776 | ▼ 11% |
| Retained profit | € 413,901 | € 366,364 | € 315,050 | € 254,734 | ▼ 19% |
| Balance sheet total | € 493,220 | € 444,580 | € 600,242 | € 489,393 | ▼ 18% |
Key figures of Cystic Fibrosis Europe, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Cystic Fibrosis Europe?
What happened at Cystic Fibrosis Europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 60,316. Source: NBB ↗
- New establishment in Oudergem. KBO
- Start of the company according to the CBE. KBO
In short
From € 19,210 loss in 2022 to € 60,316 loss in 2025.
Paid € 537 in corporate taxes since 2022.
A new publication or filing at Cystic Fibrosis Europe? We notify you, reason included.
Follow Cystic Fibrosis EuropeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Establishments
Establishment units
Physical locations of this company
Joseph Borlélaan 12
1160 Oudergem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0640.670.746
- VAT number
- BE 0640.670.746
- Registered office
- Joseph Borlélaan 12, 1160 Oudergem
- Names & denominations
- Cystic Fibrosis Europe · "CF Europe" en "CFE"
- Enterprise type
- Rechtspersoon
- Legal form
- International non-profit association
- Legal situation
- Normale toestand
- Start date
- 7 October 2015
- Peppol
- Active · Active since 9 Dec 2025
- Activities · NACE
Verenigingen op het vlak van ziektepreventie en gezondheidsbevordering